Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 7/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206707 | 0.92 | ICMT (0.53) | TSHRANO1MPOMTNR1AMTNR1B | |
| SCHEMBL5209045 | 0.87 | CDK2 (0.49) | MTNR1AMTNR1BMAPTNPSR1GPR84 | |
| SCHEMBL5210851 | 0.86 | MAPT (0.60) | TSHRMAPTNPSR1POLBSMN1; SMN2 | |
| SCHEMBL5207887 | 0.85 | KDM4E (0.60) | MPONOTUMMTNR1AMTNR1BKDM4E | |
| SCHEMBL5213599 | 0.81 | ICMT (0.61) | KDM4EMAPTNPSR1ICMT | |
| SCHEMBL5211211 | 0.81 | HTR1D (0.48) | MAPTNPSR1ICMTPOLBSMN1; SMN2 | |
| SCHEMBL5214070 | 0.81 | PPARG (0.57) | KDM4EMAPTSLC6A4POLBSMN1; SMN2 | |
| SCHEMBL5213952 | 0.81 | ICMT (0.47) | KDM4EMAPTNPSR1ICMTSMN1; SMN2 | |
| SCHEMBL5207800 | 0.80 | ICMT (0.51) | MTNR1AMTNR1BKDM4EICMT | |
| SCHEMBL5208637 | 0.79 | ICMT (0.49) | MAPTICMTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288564-B2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 2007-10-30 | — | — | US | claimed |
| US-7288564-B2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 2007-10-30 | — | — | US | disclosed |
| EP-1343757-B1 | INDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20040092569-A1 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-1343757-A1 | INDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050031-A1 | INDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092569-A1 | Indole derivatives | PTGER4, PTGER1, TRPV4 | TSHR 1260/4885ANO1 2417/4885MPO 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.